In the ongoing battle against obesity and type 2 diabetes, two medications — Zepbound (tirzepatide) and Wegovy (semaglutide) — have emerged as leading treatments. Both are FDA-approved and have demonstrated effectiveness in weight management, but they differ in mechanisms, dosage, and overall effectiveness. If you’re considering either of these drugs for weight loss or for weight loss of your kids, here’s what you need to know, according to VeryWellHealth.com.
How do these medications work?
Zepbound and Wegovy belong to a class of medications known as GLP-1 receptor agonists, which help regulate blood sugar levels and metabolism. However, Zepbound (tirzepatide) has an added advantage: It is also a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. This dual action may contribute to greater weight loss and improved blood sugar control compared to semaglutide.
Both drugs slow down gastric emptying, making you feel fuller for longer, which helps reduce appetite and calorie intake. Research suggests that tirzepatide’s additional GIP receptor activation enhances its effectiveness.
Effectiveness for weight loss
Both medications are effective for weight loss, but studies suggest tirzepatide may be superior. Consider these findings:
- A 2024 study found that patients with obesity or overweight treated with tirzepatide experienced greater weight loss compared to those on semaglutide.
- A 2023 review revealed that tirzepatide users had an average total body weight loss of 17.8%, compared to 12.4% for semaglutide users.
- A 2021 study indicated tirzepatide was more effective than semaglutide in reducing blood sugar levels in people with type 2 diabetes over 40 weeks.
While these studies indicate tirzepatide’s potential advantages, it is important to note that the dosages in these studies were not always equal, which could impact the results. More direct comparisons are needed to confirm these findings.
Dosage differences
Both medications are taken via weekly subcutaneous injections, but their dosage regimens differ:
Tirzepatide (Zepbound) Dosage:
- Initial dose: 2.5 mg per week for four weeks
- Dose increases: Gradual increments of 2.5 mg every four weeks
- Maximum dose: 15 mg per week
Semaglutide (Wegovy) Dosage:
- Initial dose: 0.25 mg per week for four weeks
- Dose increases: Gradually up to 0.5, 1.0, 1.7, or 2.4 mg
- Maximum dose: 2.4 mg once weekly
Side effects and safety
Both medications share common side effects, including:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Stomach discomfort
- Fatigue
- Heartburn
Muscle loss has been reported in patients taking both medications, but this can also occur with significant weight loss.
Cost and availability
One major concern for many patients is affordability. The annual cost for GLP-1 receptor agonist drugs can range from $5,000 to $10,000 in the U.S. While tirzepatide tends to be more cost-effective than semaglutide, prices depend on insurance coverage and availability of manufacturer discounts.
Previously, both drugs experienced shortages, leading to increased demand for compounded versions. However, as of February 2025, neither medication was still in shortage.
Can you switch between the two?
Yes, switching between these medications is not uncommon, especially if one is not yielding the desired results. However, a healthcare provider should always guide the transition to ensure safety and effectiveness.
Which one should you choose?
Both Zepbound and Wegovy can effectively aid in weight loss, but the choice depends on individual factors such as:
- Effectiveness: Tirzepatide may offer superior weight loss benefits.
- Cost: Tirzepatide tends to be more affordable, but insurance coverage varies.
- Age Restrictions: Tirzepatide is not currently approved for use in children.
- Tolerability: Both drugs have similar side effects, but individual experiences may differ.
GLP-1 Drugs for Type 2 diabetes may not be safe for Type 1 patients
Then there’s this. Medications originally developed to manage type 2 diabetes may not be suitable for patients with type 1 diabetes, according to researchers from the Johns Hopkins Bloomberg School of Public Health.
A recent study highlights concerns regarding the use of GLP-1 receptor agonists among type 1 diabetes patients. GLP-1 receptor agonists have been available for over two decades to help manage type 2 diabetes. Over time, some were also approved for reducing cardiovascular disease risk and treating obesity. However, type 1 diabetes patients have started using these drugs even though they were excluded from clinical trials due to concerns about hypoglycemia (dangerously low blood sugar levels).
Unlike type 2 diabetes, which is characterized by insulin resistance, type 1 diabetes is an autoimmune condition where the body does not produce insulin, requiring lifelong insulin therapy. The study, which analyzed over 200,000 anonymized medical records from 2008 to 2023, found a significant increase in obesity rates among individuals with type 1 diabetes across all age groups and ethnic backgrounds.
The findings, published on March 3 in Diabetes, Obesity and Metabolism, emphasize the need for more research on the use of GLP-1 receptor agonists in type 1 diabetes patients. Senior author Dr. Jung-Im Shin, an associate professor at the Bloomberg School’s Department of Epidemiology, commented:
These findings highlight the urgent need for better data — including clinical trials — on the effectiveness and safety of GLP-1 receptor agonists in people with type 1 diabetes, to inform clear guidelines on their use in these patients.
As usual, more studies need to happen, and researchers have their work cut out for them.
Your responses and feedback are welcome!
Source: “Zepbound (Tirzepatide) vs. Wegovy (Semaglutide) for Weight Loss,” VeryWellHealth.com, 3/31/25
Source: “Weight-Loss Drug Use Has Risen Sharply Among Children and Adults With Type 1 Diabetes,” John Hopkins Bloomberg School of Public Health, 3/26/25
Source: “Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States,” Diabetes, Obesity and Metabolism, 3/3/25
Image by Chokniti Khongchum/Pexels
FAQs and Media Requests: 
